Study: NCT00433173

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intravenous glucose tolerance test
Description: The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous glucose tolerance test
Description: The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravenous glucose tolerance test
Description: The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: transdermal 7.5 g/per day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testosterone
Description: transdermal 7.5 g/per day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anastrozole
Description: tablet (per oral) 10.0 mg/ daily 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate implant
Description: single depot injection 10.8 mg 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate implant
Description: single depot injection 10.8 mg 3 months

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: aerobic capacity (VO2 Max)
Description: This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic capacity (VO2 Max)
Description: This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aerobic capacity (VO2 Max)
Description: This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: 1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: 1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: 1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: muscle biopsy
Description: Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle biopsy
Description: Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: muscle biopsy
Description: Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: measurement of resting metabolic rate (energy expenditure)
Description: Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: measurement of resting metabolic rate (energy expenditure)
Description: Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: measurement of resting metabolic rate (energy expenditure)
Description: Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dual energy x-ray absorptiometry
Description: Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual energy x-ray absorptiometry
Description: Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual energy x-ray absorptiometry
Description: Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fasting oral glucose tolerance test
Description: To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fasting oral glucose tolerance test
Description: To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fasting oral glucose tolerance test
Description: To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.